Neurocrine Biosciences | NBIX - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
AbbVie USD 6.72B 1.99B 2026-06
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
ALKERMES USD -65.93M 17.65M 2026-06
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Amgen USD 4.61B 777M 2026-06
Biogen USD -243.8M 758.1M 2026-06
BioMarin Pharmaceutical USD 105.6M 24.04M 2026-06
Cytokinetics USD -179.17M 2.05M 2026-06
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
Exelixis USD 248.41M 2.93M 2026-06
Gilead Sciences USD 3.85B 1.17B 2026-06
Halozyme Therapeutics USD -63.72M 1.95M 2026-06
Incyte USD 700.4M 376.22M 2026-06
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Neurocrine Biosciences USD 219.9M 5.3M 2026-06
Pfizer USD 667M 4.32B 2026-06
Prothena USD 25.79M 53M 2026-03
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Repligen USD 21.13M 1.15M 2026-06
Rigel Pharmaceuticals USD 14.06M 13.61M 2024-09
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
Teva Pharmaceutical Industries USD 235M 523M 2026-06
Ultragenyx Pharmaceutical USD -75M 141M 2026-06
Vertex Pharmaceuticals USD 1.27B 129.9M 2026-06